William DeGrado

Last updated

William F. DeGrado
WilliamDeGrado photo.gif
Born1955
NationalityAmerican
Alma materKalamazoo College
University of Chicago
Known forDe novo protein design and small molecule drug discovery
Scientific career
FieldsChemistry, Biochemistry and Biophysics
InstitutionsUniversity of California, San Francisco

William (Bill) DeGrado (born 1955) is a professor at the University of California, San Francisco, where he is the Toby Herfindal Presidential Professor of Entrepreneurship and Innovation in the Department of Pharmaceutical Chemistry. [1] As an early pioneer of protein design, he coined the term de novo protein design. He is also active in discovery of small molecule drugs for a variety of human diseases. He is a member of the U.S. National Academy of Sciences (1999), American Academy of Arts & Sciences (1997) and National Academy of Inventors. He also is a scientific cofounder of Pliant therapeutics.

Contents

Early life and Education

Following high school graduation, DeGrado worked in a coat rack factory, an experience that motivated him to further his education. He attended colleges in the Chicago suburbs, while running a lawn-mowing service. About this time, his father, Jim DeGrado, designed the highly successful Red Solo Cup, while working as a commercial artist at Solo. In appreciation, Solo Cup offered DeGrado, a scholarship for the final two years of college, which DeGrado completed at Kalamazoo College.

DeGrado received his B.A. in chemistry from Kalamazoo College (1978) and a doctorate in organic chemistry from the University of Chicago (1981).

Industrial and academic career

After receiving his PhD in organic chemistry from the University of Chicago (1981), DeGrado began work at DuPont as a research chemist, eventually becoming a senior director for small molecule therapeutics in DuPont Merck's medicinal chemistry department. In 1995 he moved to the University of Pennsylvania, where he was a professor in the biochemistry and biophysics department as well as an adjunct professor in the department of chemistry. Since 2011 he has been at the University of California, San Francisco School of Pharmacy, where he is the Toby Herfindal Presidential Professor of Entrepreneurship and Innovation. He is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases at UCSF.

Research

Starting in the 1980's DeGrado's group developed the approach of de novo protein design, a term they coined to describe the design of proteins from first principles rather than through modification of natural protein sequences. [2] [3] [4] They pioneered parametric approaches to the design of water-soluble 4-helix (alpha4) and 3-helix bundles (alpha3D), and ion channel peptides. The protein, alpha3D, was notable at the time, because it was the premier example of a de novo protein, which was biologically expressed, structurally validated, and whose sequence and structure were not based on the sequence or the precise tertiary structure of a natural protein. [5] The sequence of alpha3D was designed using the computational sidechain repacking algorithms that had recently been developed by Ponders & Richards, [6] [7] [8] [9] Desjarlais & Handel, Dahiyat & Mayo. The folding kinetics of alpha3D are among the most extensively characterized of single-domain proteins, [10] [11] and it has been used as a template for design of metalloproteins. [12] The company Arcellex [13] used alpha3D [14] as a starting point for design of chimeric antigen receptors (CARs). Clinical data announced in 2020 showed deep and durable responses of multiple myeloma, illustrating the potential of de novo proteins for treatment of human disease. [15]

With Angela Lombardi (University of Naples), Les Dutton and Michael Therien (Duke University) DeGrado has also designed numerous proteins that mimic many of the catalytic and electron relay properties of heme and non-heme iron proteins, including a transmembrane protein capable of shuttling electrons across membranes. [16] His group has also designed the first examples of de novo ion and proton channels.

Because the original approaches to de novo protein design focused on physical chemical principles it was easily extended to design biologically active polymers and foldamers (short homogeneous, sequence-specific polymers that fold into unique structures). [17] This work led to the design of Brilacidin, [18] which is currently in phase II clinical trials.

Contributions to Pharmaceutical Chemistry

DeGrado contributed significantly to the development of Brilacidin, which is in clinical trials for several indications. DeGrado's group also has contributed to the development of small molecule antagonists of integrins [19] that reached clinical trials. [20] His work on this subject with Dean Sheppard [21] also formed the basis for founding Pliant Pharmaceuticals, [22] a company conducting clinical trials on idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis.

Awards

Related Research Articles

<span class="mw-page-title-main">Alpha helix</span> Type of secondary structure of proteins

An alpha helix is a sequence of amino acids in a protein that are twisted into a coil.

<span class="mw-page-title-main">Hemoprotein</span> Protein containing a heme prosthetic group

A hemeprotein, or heme protein, is a protein that contains a heme prosthetic group. They are a very large class of metalloproteins. The heme group confers functionality, which can include oxygen carrying, oxygen reduction, electron transfer, and other processes. Heme is bound to the protein either covalently or noncovalently or both.

A coiled coil is a structural motif in proteins in which 2–7 alpha-helices are coiled together like the strands of a rope. They have been found in roughly 5-10% of proteins and have a variety of functions. They are one of the most widespread motifs found in protein-protein interactions. To aid protein study, several tools have been developed to predict coiled-coils in protein structures. Many coiled coil-type proteins are involved in important biological functions, such as the regulation of gene expression — e.g., transcription factors. Notable examples are the oncoproteins c-Fos and c-Jun, as well as the muscle protein tropomyosin.

<span class="mw-page-title-main">Peptidomimetic</span> Class of compounds designed to mimic features of peptides

A peptidomimetic is a small protein-like chain designed to mimic a peptide. They typically arise either from modification of an existing peptide, or by designing similar systems that mimic peptides, such as peptoids and β-peptides. Irrespective of the approach, the altered chemical structure is designed to advantageously adjust the molecular properties such as stability or biological activity. This can have a role in the development of drug-like compounds from existing peptides. Peptidomimetics can be prepared by cyclization of linear peptides or coupling of stable unnatural amino acids. These modifications involve changes to the peptide that will not occur naturally. Unnatural amino acids can be generated from their native analogs via modifications such as amine alkylation, side chain substitution, structural bond extension cyclization, and isosteric replacements within the amino acid backbone. Based on their similarity with the precursor peptide, peptidomimetics can be grouped into four classes where A features the most and D the least similarities. Classes A and B involve peptide-like scaffolds, while classes C and D include small molecules.

<span class="mw-page-title-main">Foldamer</span> Chain molecule which folds in predictable ways while in solution

In chemistry, a foldamer is a discrete chain molecule (oligomer) that folds into a conformationally ordered state in solution. They are artificial molecules that mimic the ability of proteins, nucleic acids, and polysaccharides to fold into well-defined conformations, such as α-helices and β-sheets. The structure of a foldamer is stabilized by noncovalent interactions between nonadjacent monomers. Foldamers are studied with the main goal of designing large molecules with predictable structures. The study of foldamers is related to the themes of molecular self-assembly, molecular recognition, and host–guest chemistry.

A polyproline helix is a type of protein secondary structure which occurs in proteins comprising repeating proline residues. A left-handed polyproline II helix is formed when sequential residues all adopt (φ,ψ) backbone dihedral angles of roughly and have trans isomers of their peptide bonds. This PPII conformation is also common in proteins and polypeptides with other amino acids apart from proline. Similarly, a more compact right-handed polyproline I helix is formed when sequential residues all adopt (φ,ψ) backbone dihedral angles of roughly and have cis isomers of their peptide bonds. Of the twenty common naturally occurring amino acids, only proline is likely to adopt the cis isomer of the peptide bond, specifically the X-Pro peptide bond; steric and electronic factors heavily favor the trans isomer in most other peptide bonds. However, peptide bonds that replace proline with another N-substituted amino acid are also likely to adopt the cis isomer.

A helix bundle is a small protein fold composed of several alpha helices that are usually nearly parallel or antiparallel to each other.

<span class="mw-page-title-main">Roger D. Kornberg</span> American biochemist and professor of structural biology

Roger David Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information from DNA is copied to RNA, "the molecular basis of eukaryotic transcription."

Graham R. Fleming is a professor of chemistry at the University of California, Berkeley and member of the Kavli Energy NanoScience Institute based at UCB.

<span class="mw-page-title-main">Arginylglycylaspartic acid</span> Chemical compound

Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. The discovery of RGD and elucidation of how RGD binds to integrins has led to the development of a number of drugs and diagnostics, while the peptide itself is used ubiquitously in bioengineering. Depending on the application and the integrin targeted, RGD can be chemically modified or replaced by a similar peptide which promotes cell adhesion.

<span class="mw-page-title-main">Stephen J. Benkovic</span> American chemist

Stephen James Benkovic is an American chemist known for his contributions to the field of enzymology. He holds the Evan Pugh University Professorship and Eberly Chair in Chemistry at The Pennsylvania State University. He has developed boron compounds that are active pharmacophores against a variety of diseases. Benkovic has concentrated on the assembly and kinetic attributes of the enzymatic machinery that performs DNA replication, DNA repair, and purine biosynthesis.

<span class="mw-page-title-main">Paul Schimmel</span> American chemist

Paul Reinhard Schimmel is an American biophysical chemist and translational medicine pioneer.

<span class="mw-page-title-main">Nenad Ban</span> Croatian biochemist

Nenad Ban is a biochemist born in Zagreb, Croatia who currently works at the ETH Zurich, Swiss Federal Institute of Technology, as a professor of Structural Molecular Biology. He is a pioneer in studying gene expression mechanisms and the participating protein synthesis machinery.

Circumsporozoite protein (CSP) is a secreted protein of the sporozoite stage of the malaria parasite and is the antigenic target of RTS,S and other malaria vaccines. The amino-acid sequence of CSP consists of an immunodominant central repeat region flanked by conserved motifs at the N- and C- termini that are implicated in protein processing as the parasite travels from the mosquito to the mammalian vector. The amino acid sequence of CSP was determined in 1984.

<span class="mw-page-title-main">Stapled peptide</span>

A stapled peptide is a modified peptide, typically in an alpha-helical conformation, that is constrained by a synthetic brace ("staple"). The staple is formed by a covalent linkage between two amino acid side-chains, forming a peptide macrocycle. Staples, generally speaking, refer to a covalent linkage of two previously independent entities. Peptides with multiple, tandem staples are sometimes referred to as stitched peptides. Among other applications, peptide stapling is notably used to enhance the pharmacologic performance of peptides.

Virginia Wood Cornish is the Helena Rubinstein Professor of Chemistry at Columbia University.

<span class="mw-page-title-main">Mei Hong (chemist)</span> Chinese-American chemist

Mei Hong is a Chinese-American biophysical chemist and professor of chemistry at the Massachusetts Institute of Technology. She is known for her creative development and application of solid-state nuclear magnetic resonance (ssNMR) spectroscopy to elucidate the structures and mechanisms of membrane proteins, plant cell walls, and amyloid proteins. She has received a number of recognitions for her work, including the American Chemical Society Nakanishi Prize in 2021, Günther Laukien Prize in 2014, the Protein Society Young Investigator award in 2012, and the American Chemical Society’s Pure Chemistry award in 2003.

Derek Dek Woolfson is a British chemist and biochemist. He is a professor of chemistry and biochemistry. and director of the Bristol BioDesign Institute at the University of Bristol, and founder of synthetic biology spin-out company Rosa Biotech.

James Allen Wells is a Professor of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology at the University of California, San Francisco (UCSF) and a member of the National Academy of Sciences. He received his B.A. degrees in biochemistry and psychology from University of California, Berkeley in 1973 and a PhD in biochemistry from Washington State University with Ralph Yount, PhD in 1979. He completed his postdoctoral studies at Stanford University School of Medicine with George Stark in 1982. He is a pioneer in protein engineering, phage display, fragment-based lead discovery, cellular apoptosis, and the cell surface proteome.

Coiled-coil drug delivery systems refer to drug delivery systems utilizing coiled-coil motifs capable of delivering disease-treating therapies, imaging agents, and vaccines to patients systemically or specifically. These systems are a form of peptide therapeutics and are capable of being engineered and finely tuned into different types of drug delivery vehicles based on the specific application required. The goal of a coiled-coil drug delivery system is to deliver cargo such as medication, imaging agents, biological molecules, or vaccines efficiently and specifically, in order to maximize the therapeutic efficacy and minimize unwanted side effects. This is achieved through fine-tuning the factors affecting the coiled coil’s oligomerization, resulting in modular systems that are highly specific for the intended application.

References

  1. "Department of Pharmaceutical Chemistry". UCSF Department of Pharmaceutical Chemistry. January 10, 2017. Retrieved February 8, 2023.
  2. Regan, Lynne; DeGrado, William F. (August 19, 1988). "Characterization of a Helical Protein Designed from First Principles". Science. 241 (4868): 976–978. Bibcode:1988Sci...241..976R. doi:10.1126/science.3043666. ISSN   0036-8075. PMID   3043666.
  3. DeGrado, William F.; Wasserman, Zelda R.; Lear, James D. (February 3, 1989). "Protein Design, a Minimalist Approach". Science. 243 (4891): 622–628. Bibcode:1989Sci...243..622D. doi:10.1126/science.2464850. ISSN   0036-8075. PMID   2464850.
  4. Bryson, James W.; Betz, Stephen F.; Lu, Helen S.; Suich, Daniel J.; Zhou, Hongxing X.; O'Neil, Karyn T.; DeGrado, William F. (November 10, 1995). "Protein Design: A Hierarchic Approach". Science. 270 (5238): 935–941. Bibcode:1995Sci...270..935B. doi:10.1126/science.270.5238.935. ISSN   0036-8075. PMID   7481798. S2CID   31116489.
  5. Walsh, Scott T. R.; Cheng, Hong; Bryson, James W.; Roder, Heinrich; DeGrado, William F. (May 11, 1999). "Solution structure and dynamics of a de novo designed three-helix bundle protein". Proceedings of the National Academy of Sciences. 96 (10): 5486–5491. Bibcode:1999PNAS...96.5486W. doi: 10.1073/pnas.96.10.5486 . ISSN   0027-8424. PMC   21886 . PMID   10318910.
  6. Desjarlais, John R.; Handel, Tracy M. (1995). "De novo design of the hydrophobic cores of proteins". Protein Science. 4 (10): 2006–2018. doi:10.1002/pro.5560041006. ISSN   0961-8368. PMC   2142989 . PMID   8535237.
  7. Dahiyat, Bassil I.; Mayo, Stephen L. (1996). "Protein design automation". Protein Science. 5 (5): 895–903. doi:10.1002/pro.5560050511. ISSN   0961-8368. PMC   2143401 . PMID   8732761.
  8. Dahiyat, Bassil I.; Mayo, Stephen L. (October 3, 1997). "De Novo Protein Design: Fully Automated Sequence Selection". Science. 278 (5335): 82–87. doi:10.1126/science.278.5335.82. ISSN   0036-8075. PMID   9311930.
  9. Ponder, Jay W.; Richards, Frederic M. (1987). "Tertiary templates for proteins". Journal of Molecular Biology. 193 (4): 775–791. doi:10.1016/0022-2836(87)90358-5. ISSN   0022-2836. PMID   2441069.
  10. Chung, Hoi Sung; Piana-Agostinetti, Stefano; Shaw, David E.; Eaton, William A. (September 25, 2015). "Structural origin of slow diffusion in protein folding". Science. 349 (6255): 1504–1510. Bibcode:2015Sci...349.1504C. doi:10.1126/science.aab1369. ISSN   0036-8075. PMC   6260792 . PMID   26404828.
  11. Zhu, Yongjin; Alonso, Darwin O. V.; Maki, Kosuke; Huang, Cheng-Yen; Lahr, Steven J.; Daggett, Valerie; Roder, Heinrich; DeGrado, William F.; Gai, Feng (December 11, 2003). "Ultrafast folding of α3D: A de novo designed three-helix bundle protein". Proceedings of the National Academy of Sciences. 100 (26): 15486–15491. Bibcode:2003PNAS..10015486Z. doi: 10.1073/pnas.2136623100 . ISSN   0027-8424. PMC   307594 . PMID   14671331.
  12. Mocny, Catherine S.; Pecoraro, Vincent L. (August 18, 2015). "De Novo Protein Design as a Methodology for Synthetic Bioinorganic Chemistry". Accounts of Chemical Research. 48 (8): 2388–2396. doi:10.1021/acs.accounts.5b00175. ISSN   0001-4842. PMC   5257248 . PMID   26237119.
  13. "Arcellx Cell Therapies for Cancer and Autoimmune Diseases". Arcellx. February 6, 2023. Retrieved February 8, 2023.
  14. Qin, Haiying; Edwards, Justin P.; Zaritskaya, Liubov; Gupta, Ankit; Mu, C. Jenny; Fry, Terry J.; Hilbert, David M.; LaFleur, David W. (2019). "Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells". Molecular Therapy. 27 (7): 1262–1274. doi:10.1016/j.ymthe.2019.04.010. PMC   6612629 . PMID   31043341.
  15. "Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma - Full Text View". ClinicalTrials.gov. November 7, 2019. Retrieved February 8, 2023.
  16. Korendovych, Ivan V.; DeGrado, William F. (2020). "De novo protein design, a retrospective". Quarterly Reviews of Biophysics. 53: e3. doi:10.1017/S0033583519000131. ISSN   0033-5835. PMC   7243446 . PMID   32041676.
  17. Cheng, Richard P.; Gellman, Samuel H.; DeGrado, William F. (October 1, 2001). "β-Peptides: From Structure to Function". Chemical Reviews. 101 (10): 3219–3232. doi:10.1021/cr000045i. ISSN   0009-2665. PMID   11710070.
  18. Tew, Gregory N.; Scott, Richard W.; Klein, Michael L.; DeGrado, William F. (January 19, 2010). "De Novo Design of Antimicrobial Polymers, Foldamers, and Small Molecules: From Discovery to Practical Applications". Accounts of Chemical Research. 43 (1): 30–39. doi:10.1021/ar900036b. ISSN   0001-4842. PMC   2808429 . PMID   19813703.
  19. Bach, Alvin C.; Espina, J. Robert; Jackson, Sharon A.; Stouten, Pieter F. W.; Duke, Jodie L.; Mousa, Shaker A.; DeGrado, William F. (January 1, 1996). "Type II' to Type I β-Turn Swap Changes Specificity for Integrins". Journal of the American Chemical Society. 118 (1): 293–294. doi:10.1021/ja953163+. ISSN   0002-7863.
  20. Mousa, Shaker A.; DeGrado, William F.; Mu, Dun-Xu; Kapil, Ram P.; Lucchesi, Benedict R.; Reilly, Thomas M. (1996). "Oral Antiplatelet, Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Antagonist". Circulation. 93 (3): 537–543. doi:10.1161/01.cir.93.3.537. ISSN   0009-7322. PMID   8565173.
  21. Reed, Nilgun I.; Jo, Hyunil; Chen, Chun; Tsujino, Kazuyuki; Arnold, Thomas D.; DeGrado, William F.; Sheppard, Dean (May 20, 2015). "The α v β 1 integrin plays a critical in vivo role in tissue fibrosis". Science Translational Medicine. 7 (288): 288ra79. doi:10.1126/scitranslmed.aaa5094. ISSN   1946-6234. PMC   4461057 . PMID   25995225.
  22. "Pliant". Pliant. January 5, 2023. Retrieved February 8, 2023.
  23. "The Protein Society : Protein Society Awards". The Protein Society. Retrieved February 8, 2023.
  24. "Recipients | ACS Division of Biological Chemistry Website". www.divbiolchem.org. Retrieved March 22, 2018.